清水河县肛肠医院专科在哪点(呼市内痔疮的价格) (今日更新中)

LOS ANGELES, May 29 (Xinhua) -- Nineteen percent of

BEIJING, Feb.14 (Xinhua) - Shanghai General Motors Co. will recall 2,806 imported Cadillac CTS vehicles in China to repair faulty track bars to prevent safety risks, China's quality watchdog said on Monday.The recall, which is set to begin on March 21, includes models that were produced between June 16, 2008 and April 20, 2009, the General Administration of Quality Supervision, Inspection and Quarantine said in a statement on its website.The statement said that the company would repair or replace the rear suspension track bars of the recalled vehicles because some nuts on the bars are likely to loosen and cause worn screw threads.This could lead to a loosened track bar under extreme conditions, which is unsafe when traveling fast, it said.The company is to contact car owners to provide free checks and repairs. Owners may also contact the automaker on its free phone service (telephone number: 8008201902) for more information and to make appointments.

BEIJING, April 12 (Xinhuanet) -- A new research indicats taking vitamin D could ward off vision loss from age-related macular degeneration (AMD) in women younger than 75, according to media reports on Tuesday.In the research, women under 75 who consumed sufficient vitamin D cut their risk of developing early age-related AMD, a leading cause of vision loss and blindness, by 59 percent when compared to women with vitamin D-poor diets.Researchers found that vitamin D levels among patients in the study were most affected by the amount of vitamin D they consumed, through certain fish, dairy, eggs, and leafy greens, not by the amount of outdoor exposure they had. Considering many Americans are actually deficient in vitamin D, this study may offer one more reason for women to include vitamin D-rich foods in the diet, said the lead author on the study, Amy Millen of the University of Buffalo.

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

来源：资阳报